Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05722210 · ClinicalTrials.gov registry record

Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant

A clinical trial, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Not yet
Registry status
500
Enrollment target

NCT05722210 is a clinical trial that has not yet begun recruiting, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 500 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05722210 has not yet begun recruiting, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

NOT YET RECRUITING
Registry status
500 participants
Enrollment target

Study Summary

Background: Hematopoietic stem cell transplant (HSCT) is a common treatment for many cancers and other illnesses. But many people who have HSCT go on to develop liver dysfunction. Researchers want to know more about how and why this happens. In this natural history study, they will try to learn what factors lead to liver dysfunction; how underlying liver disease may affect the results of HSCT; and how HSCT may contribute to liver dysfunction. Objective: To understand the links between HSCT and liver dysfunction. Eligibility: Adults aged 18 years or older and children 3 to 17 years who are being evaluated for HSCT. Design: This study involves 11 visits in 4 years. Most visits will be in the first year. Before and after their HSCT, participants will undergo these tests: Physical exam, including blood tests and a test of heart function. Participants will provide stool samples. Liver biopsies. Samples of liver tissue will be removed. This may be done either by inserting a needle through the right side of the chest, or with a thin tube threaded to the liver from a vein in the neck. Adult participants will undergo this procedure 2 times: once before the HSCT and once about a year later. Imaging scans. Participants will lie on a bed that moves into either a cylinder or a donut-shaped machine. Ultrasound. Participants will lie still. A probe that uses sound waves will be slid over their skin to get pictures of the liver. Fibroscan exam. This is like an ultrasound that uses a special probe to measure the toughness of the liver. ...

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2026-07-15
Est. Completion 2031-06-30

What the Registry Record Tells You About NCT05722210

The ClinicalTrials.gov registry entry for NCT05722210 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT05722210 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05722210 about?

NCT05722210 is a clinical study titled "Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant". Background: Hematopoietic stem cell transplant (HSCT) is a common treatment for many cancers and other illnesses. But many people who have HSCT go on to develop liver dysfunction. Researchers want to know more about how and why this happens. In this natural history study, they will try to learn wha...

What is the current status of trial NCT05722210?

This trial is currently not yet recruiting. The enrollment target is 500 participants. The study started on 2026-07-15. Estimated completion is 2031-06-30.

Who is sponsoring clinical trial NCT05722210?

This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.